AI-generated summary
The authors studied 980-nm pulsed photobiomodulation (light therapy) in mouse tumor models and report that it slowed early tumor growth by reinvigorating CD8+ T cells, without directly killing cancer cells. They describe the effect as localized to irradiated tumors and dependent on CD8+ T cells, and report no systemic toxicity. The authors also note the approach failed against pigmented B16 melanoma, possibly due to melanin absorbing the light.
- Who or what was studied
- Mice with syngeneic LLC and MC38 tumors, and pigmented B16 melanoma
- Wavelengths
- 980 nm
- Limits stated in the abstract
- The study was conducted in mouse tumor models, and the abstract does not report human data.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Melanin. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.